Kjell Mortier
Fund Manager @ Novalis Biotechnology Incubation
Ghent, Belgium
Kjell Mortier is a seed investor at Novalis Biotechnology Incubation in Ghent focused on Medical and Biopharma. Kjell Mortier is the Fund Manager of Novalis Biotechnology Incubation. Kjell attended Ghent University.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Kjell Mortier invests in
Stages Kjell Mortier invests in
Countries Kjell Mortier invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 1 (50%)
- Biopharma 1 (50%)
- Health Care 1 (50%)
- Biotechnology 1 (50%)
- Manufacturing 1 (50%)
Stage
- Seed 1 (50%)
- Series A 1 (50%)
Country
- Belgium 1 (50%)
- Portugal 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| C-mo is the solution providing a complete assessment of cough, adressing key use-cases across the patient management lifecycle. | $760.2K / Seed / Jan 31, 2023 | ||
| RheaVita is a pharmaceutical company developing continuous freeze-drying technology for biopharmaceutical products. The company technology integrates all freeze-drying process step unit operations in a continuous production line with the constant infeed of products and the concomitant outfeed of the dried product. Its manufacturing approach avoidsscale-up issues, reduces cycle times, allows fast product development, reduces time-to-market, lowers production costs, makes use of smaller manufacturing installations, requires less clean room space, provides improved quality assurance (100% inspection with inherent potential for real-time-release) and leads to improved and uniform product quality and process uniformity. | $3.1M / Series A / Jun 02, 2021 |
Co-Investors
Novalis Biotech Incubation seeds biotechnology and life sciences-related companies. We focus on early-stage start-ups and support their evolution by providing funding, sharing our professional and academic connections, and help to shape the business strategy in order to create value for all stakeholders.
Novalis Biotechnology Incubation Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jan Berghe
Managing Director & Co-Founder
|
|||
Jan Van den Berghe
Co-Founder
|
|||
|
Kjell Mortier
Fund Manager
|
|||
Wim van Criekinge
Co-Founder & Managing Director
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Kjell Mortier invest in?
Kjell Mortier invests primarily in Medical, Biopharma and Health Care startups, most often at Seed and Series A stage. Most of the 2 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Kjell Mortier?
Public channels for Kjell Mortier include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Kjell Mortier last invest?
The most recent investment recorded for Kjell Mortier closed in Jan 2023. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
